Beyond Spring Inc. BYSI
We take great care to ensure that the data presented and summarized in this overview for BeyondSpring Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BYSI
View all-
Decheng Capital LLC Menlo Park, CA4.96MShares$14.8 Million2.37% of portfolio
-
Black Rock Inc. New York, NY215KShares$641,1850.0% of portfolio
-
Capstone Capital Wealth Advisors Henderson, NV50.5KShares$150,4900.16% of portfolio
-
State Street Corp Boston, MA32.2KShares$95,9560.0% of portfolio
-
Y Intercept (Hong Kong) LTD30.7KShares$91,4170.01% of portfolio
-
Tanaka Capital Management Inc New York, NY29.5KShares$87,8290.26% of portfolio
-
Geode Capital Management, LLC Boston, MA24.4KShares$72,6160.0% of portfolio
-
Acadian Asset Management LLC Boston, MA22.6KShares$67,3330.0% of portfolio
-
Northern Trust Corp Chicago, IL18.8KShares$55,9040.0% of portfolio
-
Sg Americas Securities, LLC17.5KShares$52,2660.0% of portfolio
Latest Institutional Activity in BYSI
Top Purchases
Top Sells
About BYSI
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Insider Transactions at BYSI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|